FDA Approves Portable Photon-counting CT Scanner

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its portable photon-counting CT scanner for upper extremity imaging.

Designed for use in community and point-of-care settings, the MARS Bioimaging Extremity Scanner System delivers premium, high-resolution 3D X-ray images that visualize soft tissue, bone, blood vessels and metallic implants with clear material differentiation.

Chris Stoelhorst, chairman of MARS Bioimaging, said: “With FDA clearance, we can now scale clinical adoption of our scanners in the United States, the world’s largest CT market. This milestone supports our mission to enhance health economics and equity by expanding access to premium photon-counting CT imaging in community-based settings.”

“Achieving FDA clearance validates the safety and effectiveness of our portable photon-counting CT scanner, purpose-built for community-based settings, including clinical offices, sports medicine clinics and ambulatory service units. It is designed for clinicians to use across the diagnostic pathway, including pre- and post-surgical planning, assessment of fracture healing, and identification of implant-related complications,” added Mark Figgitt, Group COO of MARS Bioimaging, who led the FDA process.

The scanner leverages advanced photon-counting detector technology developed originally through particle physics research at the European Laboratory for Particle Physics (CERN), home of the Higgs boson discovery. MARS Bioimaging holds the exclusive license from CERN to commercialize this Medipix3 technology for medical imaging.

Rafael Ballabriga, spokesperson for the Medipix3 collaboration at CERN, said: “It is very rewarding to see a technology developed initially for High Energy Physics transferred to the medical field for the benefit of society. It was a long journey starting with the adaptation of the technology to spectroscopic X-ray imaging by the Medipix3 Collaboration. MARS then built a ground-breaking medical product around the device and overcame the many hurdles associated with achieving this major milestone of FDA approval. We congratulate them!”

Hospital for Special Surgery (HSS) in New York City, the world's leading academic medical center focused on musculoskeletal health and a MARS Bioimaging collaborator, welcomed the FDA clearance news.

HSS Managing Director, Business Development, Vijay Nair said: “We are excited to see MARS achieve this important milestone. At HSS, our physicians and innovators are committed to continuously improving patient outcomes through our work with new technologies. Our collaboration with MARS on the portable photon-counting CT scanner for upper extremities is evidence of this and has allowed us to support the development of imaging technology aimed at enhancing diagnostic patient care.”

Dr. Ojas Mahapatra, Group CEO, MARS Bioimaging, said: “FDA clearance represents a pivotal milestone for MARS Bioimaging. In addition to enabling commercial rollout in the United States, it provides important validation that supports regulatory pathways and market adoption globally.”

For more information, go to www.marsbioimaging.com.